AYLA
Closed
Ayala Pharmaceuticals inc
0.5036
+0.5036 (0%)
Last Update: 27 Jan 2023 17:30:00
Yesterday: 0.
Day's Range: 0.5036 - 0.5036
Send
sign up or login to leave a comment!
When Written:
0.5036
Ayala Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing small molecule therapeutics for cancer patients. The company was founded in 2017 and is headquartered in Rehovot, Israel, with additional offices in the United States. Ayala's lead drug candidate, AL101, is being developed for the treatment of recurrent or metastatic adenoid cystic carcinoma (ACC), a rare and aggressive cancer. The company is also developing other small molecule therapeutics for various types of cancer, including AL102 for ovarian and endometrial cancer and AL103 for prostate cancer. Ayala Pharmaceuticals went public in July 2020 through an initial public offering (IPO) on the Nasdaq stock exchange.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








